Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.

Ball B, Komrokji RS, Adès L, Sekeres MA, DeZern AE, Pleyer L, Vey N, Almeida A, Germing U, Cluzeau T, Platzbecker U, Gore SD, Fenaux P, Prebet T.

Blood Adv. 2018 Aug 28;2(16):2063-2071. doi: 10.1182/bloodadvances.2018015529.

2.

Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R.

Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G.

Am J Hematol. 2018 Jul 27. doi: 10.1002/ajh.25234. [Epub ahead of print]

PMID:
30051599
3.

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM.

Blood Adv. 2018 Jul 24;2(14):1765-1772. doi: 10.1182/bloodadvances.2018019414.

4.

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM.

Leuk Lymphoma. 2018 Jul 2:1-4. doi: 10.1080/10428194.2018.1468893. [Epub ahead of print] No abstract available.

PMID:
29963936
5.

Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.

Migdady Y, Barnard J, Al Ali N, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Sekeres MA, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):528-532. doi: 10.1016/j.clml.2018.05.016. Epub 2018 May 26.

PMID:
29937400
6.

Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.

Shammo JM, Komrokji RS.

Expert Rev Hematol. 2018 Jul;11(7):577-586. doi: 10.1080/17474086.2018.1486188. Epub 2018 Jun 19.

PMID:
29902097
7.

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM.

Blood Adv. 2018 Apr 24;2(8):923-932. doi: 10.1182/bloodadvances.2018016121.

8.

Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey.

Stahl M, Pine A, Hendrickson JE, Litzow MR, Luger SM, Stone RM, Erba HP, Kim TK, Sekeres MA, Steensma DP, Komrokji RS, Gore SD, Zeidan AM.

Leuk Lymphoma. 2018 Apr 18:1-4. doi: 10.1080/10428194.2018.1452219. [Epub ahead of print] No abstract available.

PMID:
29667455
9.

Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes.

Padron E, Ball MC, Teer JK, Painter JS, Yoder SJ, Zhang C, Zhang L, Moscinski LC, Rollison DE, Gore SD, Bejar R, Walter MJ, Sekeres MA, Komrokji RS, Epling-Burnette PK.

Blood. 2018 May 24;131(21):2402-2405. doi: 10.1182/blood-2018-01-827881. Epub 2018 Apr 16. No abstract available.

PMID:
29661788
10.

Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM.

Biol Blood Marrow Transplant. 2018 Apr 9. pii: S1083-8791(18)30159-9. doi: 10.1016/j.bbmt.2018.03.025. [Epub ahead of print]

PMID:
29649620
11.

Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes.

McGraw KL, Nguyen J, Al Ali NH, Komrokji RS, Sallman D, Zhang X, Song J, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L.

Br J Haematol. 2018 Jan 23. doi: 10.1111/bjh.15099. [Epub ahead of print] No abstract available.

PMID:
29359794
12.

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.

Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS.

Ann Hematol. 2018 Mar;97(3):435-441. doi: 10.1007/s00277-017-3194-4. Epub 2017 Nov 30.

PMID:
29189896
13.

The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.

Duong VH, Padron E, Al Ali NH, Lancet JE, Hall J, Kwok B, Zhang L, Epling-Burnette PK, List AF, Komrokji RS.

Ann Hematol. 2018 Feb;97(2):247-254. doi: 10.1007/s00277-017-3186-4. Epub 2017 Nov 22.

PMID:
29167940
14.

Myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N.

Leuk Lymphoma. 2018 Jul;59(7):1672-1676. doi: 10.1080/10428194.2017.1397663. Epub 2017 Nov 9.

PMID:
29119847
15.

Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.

Sébert M, Komrokji RS, Sekeres MA, Prebet T, Cluzeau T, Santini V, Gyan E, Sanna A, Ali NH, Hobson S, Eclache V, List A, Fenaux P, Adès L.

Leuk Res. 2017 Dec;63:72-77. doi: 10.1016/j.leukres.2017.10.013. Epub 2017 Oct 27.

PMID:
29112938
16.

A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.

Mirza AS, Lancet JE, Sweet K, Padron E, Pinilla-Ibarz J, Nardelli L, Cubitt C, List AF, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):902-907. doi: 10.1016/j.clml.2017.09.007. Epub 2017 Sep 19.

PMID:
29030092
17.

The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval.

Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e45-e53. doi: 10.1016/j.clml.2017.08.002. Epub 2017 Aug 5.

PMID:
28869184
18.

Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.

Zeidan AM, Pullarkat VA, Komrokji RS.

Crit Rev Oncol Hematol. 2017 Sep;117:57-66. doi: 10.1016/j.critrevonc.2017.07.002. Epub 2017 Jul 12. Review.

PMID:
28807236
19.

A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.

Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD.

Cancer. 2017 Oct 1;123(19):3662-3672. doi: 10.1002/cncr.30903. Epub 2017 Jul 31. Review.

PMID:
28759108
20.

Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia.

Zhang Q, Ball MC, Zhao Y, Balasis M, Letson C, Vedder A, List AF, Epling-Burnette PK, Komrokji RS, Padron E.

Leukemia. 2018 Feb;32(2):532-538. doi: 10.1038/leu.2017.184. Epub 2017 Jun 21.

PMID:
28694526
21.

TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

Kharfan-Dabaja MA, Komrokji RS, Zhang Q, Kumar A, Tsalatsanis A, Perkins J, Nishihori T, Field T, Al Ali N, Mishra A, Sallman D, Salem KZ, Zhang L, Moscinski L, Fernandez HF, Lancet J, List A, Anasetti C, Padron E.

Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):753-758. doi: 10.1016/j.clml.2017.06.003. Epub 2017 Jun 16.

PMID:
28687222
22.

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.

Miller CB, Komrokji RS, Mesa RA, Sun W, Montgomery M, Verstovsek S.

Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):479-487. doi: 10.1016/j.clml.2017.05.015. Epub 2017 May 12.

23.

Use of eltrombopag for treatment of myelodysplastic syndromes.

Komrokji RS.

Lancet Haematol. 2017 Mar;4(3):e99-e100. doi: 10.1016/S2352-3026(17)30017-0. No abstract available.

PMID:
28257755
24.

Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.

Apuri S, Al Ali N, Padron E, Lancet JE, List AF, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):211-214. doi: 10.1016/j.clml.2016.10.003. Epub 2017 Jan 10.

PMID:
28185797
25.

Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.

Garcia-Manero G, Montalban-Bravo G, Berdeja JG, Abaza Y, Jabbour E, Essell J, Lyons RM, Ravandi F, Maris M, Heller B, DeZern AE, Babu S, Wright D, Anz B, Boccia R, Komrokji RS, Kuriakose P, Reeves J, Sekeres MA, Kantarjian HM, Ghalie R, Roboz GJ.

Cancer. 2017 May 15;123(6):994-1002. doi: 10.1002/cncr.30533. Epub 2017 Jan 17.

26.

Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.

Griffin PT, Komrokji RS, Sweet K, Al Ali NH, Padron E, Kubal TE, List AF, Lancet JE.

Am J Hematol. 2017 Mar;92(3):232-237. doi: 10.1002/ajh.24627. Epub 2017 Feb 3.

27.

Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.

Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E.

Lancet Oncol. 2017 Jan;18(1):112-121. doi: 10.1016/S1470-2045(16)30627-1. Epub 2016 Dec 4.

PMID:
27927582
28.

Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia.

Coombs CC, Sallman DA, Devlin SM, Dixit S, Mohanty A, Knapp K, Al Ali NH, Lancet JE, List AF, Komrokji RS, Padron E, Arcila ME, Klimek VM, van den Brink MR, Tallman MS, Levine RL, Rampal RK, Rapaport F.

Haematologica. 2016 Nov;101(11):e457-e460. Epub 2016 Jul 14. No abstract available.

29.

Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).

DeZern AE, Zeidan AM, Barnard J, Hand W, Al Ali N, Brown F, Zimmerman C, Roboz GJ, Garcia-Manero G, Steensma DP, Komrokji RS, Sekeres MA; Evans MDS Clinical Research Consortium.

Leuk Lymphoma. 2017 Jun;58(6):1325-1331. doi: 10.1080/10428194.2016.1246726. Epub 2016 Oct 24.

30.

Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation.

Nassereddine S, Nishihori T, Padron E, Mahfouz R, Bazarbachi A, Komrokji RS, Kharfan-Dabaja MA.

Clin Lymphoma Myeloma Leuk. 2017 Jan;17(1):7-13. doi: 10.1016/j.clml.2016.09.005. Epub 2016 Sep 16. Review.

PMID:
27771290
31.

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.

Singer JW, Al-Fayoumi S, Ma H, Komrokji RS, Mesa R, Verstovsek S.

J Exp Pharmacol. 2016 Aug 16;8:11-9. doi: 10.2147/JEP.S110702. eCollection 2016.

32.

Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.

Pinilla-Ibarz J, Sweet KL, Corrales-Yepez GM, Komrokji RS.

Onco Targets Ther. 2016 Aug 10;9:4937-57. doi: 10.2147/OTT.S102504. eCollection 2016. Review.

33.

Ruxolitinib dose management as a key to long-term treatment success.

Mesa RA, Komrokji RS, Verstovsek S.

Int J Hematol. 2016 Oct;104(4):420-9. doi: 10.1007/s12185-016-2084-1. Epub 2016 Aug 27. Review.

PMID:
27567907
34.

Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale.

Ramadan H, Duong VH, Al Ali N, Padron E, Zhang L, Lancet JE, List AF, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S64-6. doi: 10.1016/j.clml.2016.02.009.

PMID:
27521328
35.

Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes.

Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S39-43. doi: 10.1016/j.clml.2016.02.019. Review.

PMID:
27521322
36.

Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes.

Komrokji RS.

Am Soc Clin Oncol Educ Book. 2016;35:e345-52. doi: 10.14694/EDBK_161221. Review.

37.

Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.

Basiorka AA, McGraw KL, De Ceuninck L, Griner LN, Zhang L, Clark JA, Caceres G, Sokol L, Komrokji RS, Reuther GW, Wei S, Tavernier J, List AF.

Cancer Res. 2016 Jun 15;76(12):3531-40. doi: 10.1158/0008-5472.CAN-15-1756. Epub 2016 Apr 6.

38.

Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.

Rollison DE, Shain KH, Lee JH, Hampras SS, Fulp W, Fisher K, Al Ali NH, Padron E, Lancet J, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Dalton W, List A, Komrokji RS.

Cancer Med. 2016 Jul;5(7):1694-701. doi: 10.1002/cam4.721. Epub 2016 Apr 20.

39.

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia.

McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L.

Haematologica. 2016 Aug;101(8):e320-3. doi: 10.3324/haematol.2016.143214. Epub 2016 Apr 14. No abstract available.

40.

The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure.

Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, DeZern AE, Zell K, Zimmerman C, Ali NA, Jabbour E, Greenberg MD, Kantarjian HM, Maciejewski JP, List AF, Sekeres MA; MDS Clinical Research Consortium.

Haematologica. 2016 Jun;101(6):e224-7. doi: 10.3324/haematol.2015.140962. Epub 2016 Mar 18. No abstract available.

41.

Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia.

Suleiman Y, Dalia S, Liu JJ, Bowers JW, Padron E, Lancet JE, Fulp W, Moscinski LC, Komrokji RS, Zuckerman KS, Zhang L.

Leuk Res. 2016 Mar;42:52-8. doi: 10.1016/j.leukres.2016.01.015. Epub 2016 Feb 2.

PMID:
26894965
42.

Autoimmune diseases and myelodysplastic syndromes.

Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, Padron E, Zhang L, Lancet JE, Pinilla-Ibarz J, List AF, Mufti GJ, Epling-Burnette PK.

Am J Hematol. 2016 May;91(5):E280-3. doi: 10.1002/ajh.24333. Epub 2016 Apr 4.

43.

A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).

Padron E, Dezern A, Andrade-Campos M, Vaddi K, Scherle P, Zhang Q, Ma Y, Balasis ME, Tinsley S, Ramadan H, Zimmerman C, Steensma DP, Roboz GJ, Lancet JE, List AF, Sekeres MA, Komrokji RS; Myelodysplastic Syndrome Clinical Research Consortium.

Clin Cancer Res. 2016 Aug 1;22(15):3746-54. doi: 10.1158/1078-0432.CCR-15-2781. Epub 2016 Feb 8.

44.

Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.

Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, DeZern AE, Zimmerman C, Jabbour EJ, Zell K, List AF, Kantarjian HM, Maciejewski JP, Komrokji RS; MDS Clinical Research Consortium.

Leuk Res. 2016 Feb;41:43-7. doi: 10.1016/j.leukres.2015.12.007. Epub 2015 Dec 22.

45.

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.

Komrokji RS, List AF.

Ann Oncol. 2016 Jan;27(1):62-8. doi: 10.1093/annonc/mdv488. Epub 2015 Oct 26. Review.

46.

Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.

Zeidan AM, Al Ali NH, Padron E, Lancet J, List A, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):705-10. doi: 10.1016/j.clml.2015.08.083. Epub 2015 Sep 2.

PMID:
26440749
47.

A comprehensive review of pacritinib in myelofibrosis.

Verstovsek S, Komrokji RS.

Future Oncol. 2015;11(20):2819-30. doi: 10.2217/fon.15.200. Epub 2015 Sep 14. Review.

48.

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ, Garcia-Manero G, Orazi A, Mesa R, Maciejewski JP, Fenaux P, Itzykson R, Mufti G, Solary E, List AF.

Haematologica. 2015 Sep;100(9):1117-30. doi: 10.3324/haematol.2014.114660.

49.

Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.

Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, Hoffman R.

J Clin Oncol. 2015 Nov 20;33(33):3953-60. doi: 10.1200/JCO.2015.61.6474. Epub 2015 Aug 31. Review.

50.

Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents.

Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S56-9. doi: 10.1016/j.clml.2015.03.010.

PMID:
26297279

Supplemental Content

Loading ...
Support Center